IKBKE and neoplasm: As expected, treatment with anti–PD-1 antibody, IR, or IKBKE-e ASO alone did not result in a substantial reduction in tumor growth, recapitulating the failure of immunotherapy, IR, or ARPI alone in CRPC observed in multiple clinical trials.